At baseline, most Th2 cytokines (i.e., IL-4, IL-5, IL-6, and IL-13) were elevated in the multiple myeloma patients, compared to healthy controls, and most patients had a Th1/Th2 score <1.0, suggesting Th2 dominance. Here, IL13 is linked to plasma cell myeloma.